Trevi Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for TRVI, updated each market day.
TRVI AI Sentiment
AI sees no strong directional signal for Trevi Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Trevi Therapeutics, Inc. Common Stock
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Sector
Exchange
Market Cap
$1,707,683,704
Cap Tier
Employees
34
Headquarters
NEW HAVEN, CT
Listed Since
May 3, 2019
TRVI Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TRVI Volatility
Trevi Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
